title: A qualitative study to identify factors influencing COXIB prescribed by family physicians for musculoskeletal disorders.
abstract: BACKGROUND
  Cyclo-oxygenase-2 inhibiting (COXIB) anti-inflammatories have been the drug class prescribed for a large number of cases of musculoskeletal (MSK) disorders in Canada over the past 5 years. The Alberta Improvements for MSK Disorders (AIMS) initiative sought to better understand the COXIB prescribing situation by funding several studies. The objective of this qualitative study was to determine the factors underlying primary care physicians' medication prescribing behaviour during an office visit for an MSK disorder, with particular emphasis on the prescribing of COXIBs.
  
  
  METHODS
  The target respondents were Alberta primary care physicians chosen from a stratified random sample to meet a wide range of characteristics. Individual, semi-structured interviews were used to assess decision pathways in four real cases chosen by the physician. A total of 19 interviews were conducted and analysed using an analytic inductive approach.
  
  
  RESULTS
  Factors judged as being important to decision pathways in relation to COXIB prescribing for MSK disease included safety, patient characteristics, affordability to patients, availability of samples, drug company marketing practices, habit formation, time contstraints, previous clinical experience of doctors and/or patient with certain drugs and doctors' perception of absolute versus relative risk. Interpretation. Most physicians preferentially prescribed COXIBs subsequent to a complicated, multifactorial, but essentially patient-centred, decision-making process.
authors.affiliation: Continuous Professional Learning, Faculty of Medicine and Dentistry, 2J3 Walter Mackenzie Centre Edmonton, Alberta T6G 2R7 Canada. doug.klein@ualberta.ca
authors.forename: D
authors.initials: D
authors.lastname: Klein
authors.forename: A
authors.initials: A
authors.lastname: MacDonald
authors.forename: N
authors.initials: N
authors.lastname: Drummond
authors.forename: A
authors.initials: A
authors.lastname: Cave
mesh_terms: D000416:Alberta / Q000453:epidemiology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D003657:Decision Making; D005194:Family Practice / Q000592:standards / Q000706:statistics & numerical data*; D005260:Female; D005356:Fibromyalgia / Q000188:drug therapy; D006801:Humans; D007407:Interviews as Topic; D008297:Male; D009140:Musculoskeletal Diseases / Q000188:drug therapy* / Q000453:epidemiology; D010003:Osteoarthritis / Q000188:drug therapy; D010821:Physicians, Family / Q000706:statistics & numerical data; D010818:Practice Patterns, Physicians' / Q000592:standards / Q000706:statistics & numerical data*; D036301:Qualitative Research; D012107:Research Design; D013180:Sprains and Strains / Q000188:drug therapy
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors